Shenzhen Edge Medical Co., Ltd. (Edge Medical) disclosed a Next Day Return outlining an on-market share repurchase completed on 8 October 2026.

Key transaction details • Volume: 206,200 H-shares • Repurchase price: HK$32.86–HK$33.00 per share, implying a volume-weighted average of HK$32.98 • Cash outlay: HK$6.80 million • Treatment: All repurchased shares will be held as treasury shares; none are slated for cancellation at this stage.

Post-transaction capital structure • Issued shares (excluding treasury shares): 325.23 million, down 0.06 % from 325.44 million before the buyback. • Treasury shares: 2.53 million, up from 2.32 million. • Total issued shares (including treasury stock) remain unchanged at 327.76 million.

Repurchase mandate utilisation • Shareholders authorised buybacks of up to 32.61 million shares at the 25 June 2026 AGM. • Cumulative repurchases under the mandate now stand at 911,100 shares, representing 0.28 % of the company’s outstanding shares on the mandate date. • Following the latest transaction, Edge Medical is restricted from issuing, selling or transferring shares for 30 days, until 7 November 2026, pursuant to Hong Kong Stock Exchange rules.

Compliance statement Edge Medical confirms that the repurchase was executed in accordance with the Hong Kong Main Board Listing Rules and applicable regulatory requirements. Joint Company Secretary Wu Mengyuan submitted the disclosure on 8 October 2026.